Our immune system cures us every day from cancer and infection by utilizing multiple clonotypes of T cells (multiple TCR codes) to avoid immune escape. It employs several MHC alleles (multiple antigen codes) to invoke the full power of the immune response. Our system recruits not only “killer” CD8+ cells but also ”helper” CD4+ cells and long term cures are sustained by the establishment of immune T cell memory against certain antigen codes. Continued waves of multiple T cell clonotypes overwhelm the tumor and the persistency of these waves establish long term remission.

Our approach is to recapitulate this approach, our medicines are designed to contain or induce multiple clones of CD4+ and CD8+ cells with effector and memory phenotypes to restore therapeutic immunity, and this is achieved by multiple antigens per clonotype, antigens for MHC Class I and MHC Class II and with the predominant focus on T cells from the periphery with high memory potential.
With the realization of the central role of the T cell in the Curative Immune System, the next generation of Immune Medicines will be based on enlisting optimized T cell clonotypes and overcoming immune tolerance to promote safe and durable responses. To achieve these aims, Repertoire Immune Medicines has assembled best-in-class technologies to simultaneously decode the activities of thousands of unique T cell clonotypes and to identify those with desired reactivity and function. Armed with this knowledge, the company has further generated the means by which to selectively amplify antigen-specific T cells and to safely arm them with powerful immunomodulators. We generate immune medicines that target multiple antigens in the context of patient-tailored HLA alleles and that enlist optimized T cell clonotypes armed to overcome tolerizing mechanisms within an inhospitable environment. Together this empowers their capabilities to eliminate an acute insult and to provide functional memory that augments the Immune Security Status for the future.
  1. A Phase 1/2 clinical trial testing our first generation PRIMEIL-15 alone or in combination with Keytruda® (pembrolizumab) is underway ( This program was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA.
  2. We are also developing PRIMEIL-12 and PRIMETLR to target both adaptive and innate immunity, to amplify the immune response for durability and memory.
  3. Our next wave of products in immuno-oncology aspire to off the shelf antigens and a combination of potent immune modulators.
  4. We have active discovery programs in autoimmunity and infectious diseases. The strategy in our type I diabetes (T1D) program is to identify both CD4 and CD8 antigens relevant for initiation and progression of the disease, as well as T cell receptors contributing to progression or control of disease.
  1. Repertoire Immune Medicines is dedicated to the discovery and development of a new class of T cell therapeutics for patients with solid tumors and hematologic malignancies. This novel class of T cell therapeutics directs immune power deep within the tumor microenvironment. Our goal is to provide patients with access to our investigational therapies through ongoing clinical trials.
  2. “Expanded Access,” also referred to as “compassionate use,” is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
  3. The U.S. Food and Drug Administration (FDA) has set forth guidelines when considering expanded access.
  4. According to the FDA, expanded access may be appropriate when all of the following apply:Patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition.There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.Patient enrollment in a clinical trial is not possible.Potential patient benefit justifies the potential risks of treatment.Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
  5. At this time, Repertoire Immune Medicines does not offer an expanded access program for its investigational therapies. We believe that participation in our ongoing clinical trial is the best way for patients to access our PRIME T cell therapeutics. For information about our current clinical trial, please visit with the 21st Century Cures Act, Repertoire Immune Medicines may revise this policy at any time.